title: Viruses, chemotherapy and immunity.
abstract: An increasing number of antiviral agents are presently in various stages of development and testing, and an increasing number have recently been licensed for use in humans. These drugs have been used extensively to treat viral infections in immunocompromised individuals, and these studies indicate that for many antiviral agents the response to therapy is highly dependent on the integrity of the underlying host immune response. In particular, the response to zidovudine, acyclovir and ganciclovir in persons with HIV-1 infection is highly dependent upon CD4 number, which can be considered a surrogate marker for the state of host immune function in these subjects. Responses to interferons likewise can be shown to depend on the host immune response, with responses due to both direct antiviral effects of this agent as well as immunomodulatory effects mediated through interferon-induced upregulation of HLA molecule expression. The interdependence of host immunity with antiviral efficacy is underscored by the increased antiviral drug resistance in persons with advanced degrees of chronic immunosuppression, related to the higher level of viral replication and viraemia which occurs in the absence of an effective host immune response. Further definition of the precise mechanisms of these interactions should facilitate the rational design of antiviral agents and immunomodulatory therapies to improve treatment of viral infections.
authors.affiliation: Infectious Disease Unit, Massachusetts General Hospital, Boston.
authors.forename: M J
authors.initials: MJ
authors.lastname: Koziel
authors.forename: B D
authors.initials: BD
authors.lastname: Walker
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy / Q000276:immunology; D000212:Acyclovir / Q000494:pharmacology / Q000627:therapeutic use; D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use*; D003586:Cytomegalovirus Infections / Q000188:drug therapy / Q000276:immunology; D004352:Drug Resistance, Microbial; D015774:Ganciclovir / Q000494:pharmacology / Q000627:therapeutic use; D015658:HIV Infections / Q000188:drug therapy / Q000276:immunology; D015497:HIV-1; D006566:Herpesviridae Infections / Q000188:drug therapy / Q000276:immunology; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D007372:Interferons / Q000494:pharmacology / Q000627:therapeutic use; D008285:Major Histocompatibility Complex / Q000187:drug effects; D014777:Virus Diseases / Q000188:drug therapy* / Q000276:immunology*; D015215:Zidovudine / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D000998:Antiviral Agents; D015215:Zidovudine; D007372:Interferons; D015774:Ganciclovir; D000212:Acyclovir